Biomarkers in Drug formulation

Drug formulation also covers the  surrogate end points in the use of biomarkers and patient selection or companion diagnostics and provides insights into clinical biomarker discovery and biomarker development or validation with regulatory implications. Biomarker use can improve pharmaceutical development efficiency by helping to select patients most appropriate for treatment using a given mechanism, optimize dose selection, and provide earlier confidence in accelerating or discontinuing compounds in clinical development. 

The application of biomarker technology in Drug formulation requires understanding of candidate drug pharmacology, detailed modeling of biomarker readouts relative to pharmacokinetics, rigorous validation and qualification of biomarker assays, and creative application of these elements to drug development problems.

  • Biomarker in Drug discovry
  • Biomarker in Drug Design
  • Dose selection in Biomarker
  • Biomarkers of Toxicity & Pharmacology
  • Biomarkers in dose selection
  • Evaluation of dose response

Related Conference of Biomarkers in Drug formulation

Biomarkers in Drug formulation Conference Speakers